fda compounding semaglutide warning letters october 2025 Last month, the issued 25 to telehealth companies over what it called false or misleading claims about compounded GLP-1 medications. Read more at the link in the comments below Last month, the FDA issued

Smaller individuals may be more sensitive to GI side effects at the same milligram dose

The drugs target different secondary receptors, so someone who has plateaued on tirzepatide could potentially benefit from survodutide approach to energy expenditure and liver fat metabolism

The fast losers are typically younger, have more weight to lose, started at higher body fat percentages, and often aren't training (meaning they're not preserving muscle, which makes the scale drop faster but the long-term outcome worse)

The daily dosing of both Tresiba and liraglutide probably contributes to the confusion

Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits